Inventiva Announces Initiation of Phase IIb Clinical Trial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
91
Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
  • Therapeutic candidate IVA337 is a next generation PanPPAR agonist addressing all the relevant clinical and regulatory features of NASH
  • NATIVE clinical study plans to enroll 225 patients in 12 European countries
  • Headline results are expected mid-2018

DAIX, France, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Inventiva, an emerging biopharmaceutical company developing innovative therapies notably to treat especially fibrosis, today announces the beginning of patient enrollment for its Phase IIb clinical trial (NATIVE - NASH Trial to Validate IVA337 Efficacy) evaluating the Company’s lead compound, IVA337, for the treatment of Non-Alcoholic Steatohepatitis (NASH). 

“Unlike other drugs targeting NASH, IVA337, a next generation PanPPAR agonist, addresses all the relevant clinical and regulatory features of this condition: steatosis, inflammation, ballooning and fibrosis,” said Pierre Broqua, co-founder and Chief Scientific Officer of Inventiva.

NASH is a severe and chronic form of non-alcoholic fatty liver disease that has become a leading cause to the need for liver transplantation. NASH affects over 30 million people in the United States 1 , increases 5 to 10 fold the risk of liver related mortality and is expected to become the leading cause of liver transplantation by 2020. There are no pharmaceutical treatments currently approved and treatment options are limited to lifestyle changes, weight loss and/or medical procedures, such as bariatric surgery.

NATIVE is a randomized, double-blind, placebo-controlled, multi-center, Phase IIb clinical trial in NASH patients. The study will investigate the safety and efficacy of two doses of IVA337 (800 and 1200 mg/day) over a 24-week period and will enroll up to 225 patients in 12 European countries. The primary endpoint will be based on histologically assessed improvement of the activity component of the SAF 2  score combining inflammation and ballooning, without worsening of fibrosis. 

“NASH is a highly prevalent condition with a significant unmet medical need,” said Prof. Sven Francque of the Antwerp University Hospital, and one of the trial’s Principal Investigators. “The medical community is in search of a treatment that resolves NASH without worsening fibrosis. Based on the data generated in pre-clinical models, IVA337 has the potential to meet this objective. Therefore, we are excited to further evaluate IVA337 in this Phase IIb clinical trial.”

“We are very pleased with the progress so far and the positive feed-back received from regulatory agencies as well as from the clinicians involved in the study: we look forward to the full enrollment of this study in the second half of 2017,” said Dr. Jean-Louis Abitbol, Inventiva’s CMO.

IVA337, which has demonstrated anti-fibrotic properties in several tissues alongside good clinical tolerance, is currently in a Phase IIb trial for the treatment of systemic sclerosis, another fibrotic disease with very high unmet medical needs. IVA337 has undergone a successful Phase IIa study in diabetic patients with improvements in markers of insulin resistance (HOMA-IR), and dyslipidemia (increase in circulating HDL cholesterol and decrease of circulating triglycerides). These clinical findings are extremely valuable as the physiopathology of NASH is intimately linked to obesity, IR and T2DM. Furthermore data generated in multiple relevant pre-clinical models demonstrated that IVA337 also positively impacts all hepatic lesions associated with NASH. In these pre-clinical studies, IVA337 significantly reduced steatosis, ballooning and inflammation, and reversed established liver fibrosis.

“This is a very important study in identifying a new treatment for NASH, a condition associated with increased mortality, with excess cardiovascular-, liver- and cancer-related deaths,” added Pierre Broqua. “Importantly, by measuring the efficacy of IVA337 on histological scores for ballooning and inflammation, the NATIVE study will evaluate the effects of IVA337 on the two components defining NASH resolution, a regulatory approved endpoint. The initiation of this study represents a critical milestone for our company as we continue to advance our diversified pipeline.”

Contacts

Inventiva Frédéric Cren Chief Executive Officer info@inventivapharma.com   +33 (0)3 80 44 75 00   NewCap Julien Perez / Mathilde Bohin Investor Relations inventiva@newcap.eu +33 (0)1 44 71 98 52   NewCap Nicolas Merigeau / Arthur Rouillé Media Relations inventiva@newcap.eu +33 (0)1 44 71 94 98   LifeSci Advisors Chris Maggos Investor Relations chris@lifesciadvisors.com +41 79 367 6254

About Inventiva: www.inventivapharma.com

Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

IVA337, currently in Phase IIb clinical testing for treatment of NASH and systemic sclerosis, is an anti-fibrotic treatment with a unique mechanism of action going through the activation of all three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with IVA336, a drug candidate for the treatment of three different forms of mucopolysaccharidosis (MPS I or Hurler-Sheie syndrome, MPS II or Sly syndrome and MPS VI also known as Maroteaux-Lamy syndrome), as well as a portfolio of projects in oncology.

Inventiva has signed separate strategic drug discovery partnerships with AbbVie and Boehringer Ingelheim, under which Inventiva is eligible for preclinical, clinical, regulatory and commercial milestone payments and royalties on products resulting from these partnerships. Inventiva also is leveraging its drug discovery platform to advance multiple proprietary preclinical programs and benefits from partnerships with world-leading research entities, such as the Institut Curie.

Acquired from the international pharmaceutical group Abbott (now Abbvie), Inventiva’s highly qualified staff and state-of-the-art R&D facilities, include a proprietary library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

1 Angulo et al. Hepatology 1999; 30(6):1356-62.; Minervini et al. J Hepatology 2009; 50:501–510 2  SAF is a scoring system to measure liver lesions that dissociates grade of steatosis, grade of activity, and stage of fibrosis thus enabling an easy comparison between biopsies and changes observed in paired biopsies during clinical trials.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 121

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 279

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 0

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading

Top 5 Most Recently Viewed Articles

Greenlight Re's Q3 2025: Underwriting Income Hits New Highs

Updated Category News Views 174

Greenlight Re's Impressive Financial Highlights Greenlight Capital Re, Ltd. (NASDAQ: GLRE) has made significant strides in its financial performance for the third quarter of 2025. The company has reported record underwriting income with a stellar combined ratio, making it a noteworthy player in the reinsurance industry. Strong Premium Growth In the third quarter of 2025,...

Continue Reading
Essential Insights into Recent Product Safety Recalls

Updated Category News Views 205

Understanding Recent Product Safety Recalls The U.S. Consumer Product Safety Commission (CPSC) plays a crucial role in safeguarding the public against injuries linked to consumer products. This article outlines significant recent recalls, the potential risks they pose, and what consumers should know to stay safe. Product Safety Recalls Overview The CPSC has identified...

Continue Reading
Famous Brands Launches New Dual Concept Store in Charlotte

Updated Category News Views 195

Famous Brands International Celebrates New Store Opening Famous Brands International recently marked a significant milestone with the grand opening of its latest co-branded store featuring iconic dessert brands Mrs. Fields and TCBY. This new establishment can be found nestled in a bustling shopping destination, engaging the community and sweetening up the offering for...

Continue Reading
Electric Vehicle Market Poised for Remarkable Growth Ahead

Updated Category News Views 177

Exploring the Future of the Electric Vehicle Market The electric vehicle (EV) market is on the brink of significant growth, driven by heightened global awareness surrounding climate change and the necessity to reduce carbon emissions. The market's anticipated expansion is reflective of a broader shift in transportation preferences, as more consumers seek eco-friendly...

Continue Reading
Curis Secures $12.1 Million Through Direct Stock Offering

Updated Category News Views 29

Curis Completes Significant Capital Raise of $12.1 Million Curis, Inc. (NASDAQ: CRIS), a dedicated biotechnology company focusing on innovative therapies, recently revealed a significant financial endeavor. The company is raising $12.1 million through a registered direct offering and a concurrent private placement. This strategic move enables Curis to bolster its ongoing...

Continue Reading